Monday, September 2, 2013

British cost watchdog recommends Thrombogenics eye drug

BRUSSELS (Reuters) - Belgian biotech group Thrombogenics said on Monday that its main drug Jetrea, which treats eye disease, was recommended for reimbursement by British healthcare cost watchdog NICE.

No comments:

Post a Comment

Subscribe Now: Feed Icon